Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease (OASIS-1)

NCT04899518 is registered in ClinicalTrials.gov with Allysta Pharmaceutical as lead sponsor.

NCT NCT04899518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04899518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease (OASIS-1)
Lead sponsor
Allysta Pharmaceutical
Phase
Phase 2/3
Overall status
Completed
Start date
May 19, 2021
Completion date
March 14, 2023
Enrollment
922 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye